Frequency of Asymptomatic Meibomian Gland Dysfunction in Adults: A Systematic Review and Meta-Analysis
By
Zhanar Abu
Kairolla Rakhimov
Maiya Taushanova
Indira Karibayeva
April 20, 2026
Clinical Scorecard: Frequency of Asymptomatic Meibomian Gland Dysfunction in Adults: A Systematic Review and Meta-Analysis
At a Glance
Category Detail
Condition Asymptomatic Meibomian Gland Dysfunction (MGD) Key Mechanisms Structural and functional abnormalities of meibomian glands leading to tear film instability. Target Population Adults across diverse geographic regions and ethnic groups. Care Setting Epidemiological studies and clinical assessments.
Key Highlights
Prevalence of asymptomatic MGD is 72.86% among adults. High heterogeneity in prevalence estimates across studies (I2 = 98.8%). Asymptomatic MGD may represent an early stage of the disease. Reliance on symptom-based assessments may underestimate the burden of MGD. Further standardized studies are needed for better understanding. Guideline-Based Recommendations
Diagnosis
Objective clinical signs should be used to diagnose MGD, regardless of symptoms. Management
Early identification of asymptomatic MGD is crucial to prevent progression to symptomatic dry eye disease. Monitoring & Follow-up
Regular assessments of meibomian gland function and structure are recommended. Risks
Untreated asymptomatic MGD may progress to symptomatic dry eye disease and chronic ocular surface inflammation. Patient & Prescribing Data
Adults with structural or functional abnormalities of meibomian glands.
Preventive approaches may reduce progression to symptomatic conditions.
Clinical Best Practices
Utilize objective assessments for MGD diagnosis. Educate patients on the potential for asymptomatic MGD. Implement regular monitoring for early detection of gland dysfunction. Related Resources & Content
